Daratumumab (DARA) + Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) With Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN
- Citation:
- Meeting Instance:
- SOHO 2020
- Year:
- 2020
- Type:
- Abstract
- Sub type:
- Funding:
- AFT
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3685
- Pharmas:
- Janssen
- Grants:
- Corr. Author:
- Authors:
- Ajay K. Nooka Jonathan L. Kaufman Cesar Rodriguez Andrzej Jakubowiak Leyla Shune Ashraf Badros Ajai Chari Paul G. Richardson Huiling Pei Jon Ukropec Jessica Vermeulen Daniela Hoehn Thomas S. Lin Peter M. Voorhees
- Networks:
- KANSAS, LAPS-IL057, LAPS-MA036, LAPS-OH007, MD015, NC002
- Study
- AFT-29 (GRIFFIN)
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: